滚动资讯
FierceBiotechNovartis pens $2B deal for allergy biotech with potential Xolair successorFierceBiotechAstraZeneca delivers dream result as phase 3 COPD hits breathe life into class rocked by flopsEndpoints NewsNovartis to spend up to $2B on Excellergy and its next-gen Xolair candidate10x Genomics BlogAssessing 10x Genomics (TXG) Valuation After STELA Partnership And Ongoing Cathie Wood Buying - simplywall.stEndpoints NewsRecursion appoints former Exelixis CMO; More executive moves at IncyteEndpoints NewsAstraZeneca’s COPD antibody gets Phase 3 wins in broader-than-expected populationThermo FisherWhat You Need to Know Ahead of Thermo Fisher Scientific's Earnings Release - Barchart.comAgilentAgilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Esophageal or Gastroesophageal Junction (GEJ) Carcinoma - BioSpaceLonza NewsLonza opens Media Development Lab in Singapore for cell culture media optimisation - BioSpectrum AsiaIlluminaIllumina Inc. Stock: Dominant Player in Genomic Sequencing Faces Competitive and Regulatory Challeng - AD HOC NEWSEndpoints NewsTop HHS official makes impassioned pitch to take on China biotechThermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After SHL Medical Alliance And U.S. Capacity Expansion - Yahoo Finance
FierceBiotech 2026年3月27日

Novartis pens $2B deal for allergy biotech with potential Xolair successor

Novartis pens $2B deal for allergy biotech with potential Xolair successor

原文
暂时没有全文，请查看原始来源。

目录

59 全部